Forte Biosciences, Inc. logo

Forte Biosciences, Inc. (37T)

Market Closed
14 Aug, 06:01
XMUN XMUN
NASDAQ (CM) NASDAQ (CM) Primary
XMUN XMUN
XFRA XFRA XSTU XSTU
€
4. 36
0
0%
€
137.65M Market Cap
- P/E Ratio
- Div Yield
0 Volume
- Eps
€ 4.36
Previous Close
Add Transaction
Day Range
4.36 4.36
Year Range
4.36 4.36
Want to track 37T and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Get Started For Free

Summary

37T closed Friday higher at €4.36, an increase of 0% from Thursday's close, completing a monthly increase of 0% or €0. Over the past 12 months, 37T stock gained 0%.
37T is not paying dividends to its shareholders.
The last earnings report, released on May 13, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.74%, based on the last three reports.
Forte Biosciences, Inc. has completed 1 stock splits, with the recent split occurring on Aug 28, 2024.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

37T Chart

No Data

People also search for

QU5A
Bound and Beyond Public Company Limited
€ 0.22
-0.9091%
7V0
Darwin AG
€ 6.35
0%
A28A
Affimed N.V.
€ 0.99
0%
Forte Biosciences shares surge after argenx agrees to acquire company for $2.2B

Forte Biosciences shares surge after argenx agrees to acquire company for $2.2B

Forte Biosciences (NASDAQ:FBRX) shares surged about 40% to around $76 on Monday after argenx (NASDAQ:ARGX) announced an agreement to acquire the biotechnology company in a deal valued at approximately $2.2 billion. Under the terms of the agreement, argenx will acquire all outstanding Forte Biosciences shares for $77 per share in cash.

Proactiveinvestors | 1 month ago
FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data

FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data

Forte Biosciences stock soars after early-stage data show FB102 significantly improves facial depigmentation in vitiligo with a favorable safety profile.

Zacks | 1 month ago
Forte Biosciences' FB102 Hits Key Goal in Vitiligo Study, Shows Durable Improvement

Forte Biosciences' FB102 Hits Key Goal in Vitiligo Study, Shows Durable Improvement

Forte Biosciences NASDAQ: FBRX said FB102 showed statistically significant improvement in a small placebo-controlled vitiligo study, with Chief Executive Officer Paul Wagner highlighting continued improvement after patients stopped treatment as a key feature of the results.

Marketbeat | 1 month ago

Forte Biosciences, Inc. (37T) FAQ

What is the stock price today?

The current price is €4.36.

On which exchange is it traded?

Forte Biosciences, Inc. is listed on XMUN.

What is its stock symbol?

The ticker symbol is 37T.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 137.65M.

Has Forte Biosciences, Inc. ever had a stock split?

Forte Biosciences, Inc. had 1 splits and the recent split was on Aug 28, 2024.

Forte Biosciences, Inc. Profile

Biotechnology Industry
Healthcare Sector
Paul A. Wagner CEO
XMUN Exchange
US34962G2084 ISIN
US Country
23 Employees
16 Jun 2020 Last Dividend
28 Aug 2024 Last Split
- IPO Date
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.

Contact Information

Address: 3060 Pegasus Park Drive
Phone: 310 618 6994
Download app banner
Blog Affiliate Program About Terms Privacy Help Contact Us
2026 © Marketlog. All Rights Reserved.
Play store app banner Play store app banner dark App store app banner App store app banner dark